DBV Technologies (NASDAQ:DBVT) Upgraded by Cantor Fitzgerald to Strong-Buy Rating

Cantor Fitzgerald upgraded shares of DBV Technologies (NASDAQ:DBVT) to a strong-buy rating in a research note issued to investors on Monday morning,Zacks.com reports.

DBVT has been the subject of a number of other research reports. Guggenheim started coverage on shares of DBV Technologies in a research report on Wednesday, December 3rd. They set a “buy” rating and a $35.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $35.00 target price (up previously from $20.00) on shares of DBV Technologies in a research report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DBV Technologies in a research report on Monday, December 8th. Zacks Research upgraded DBV Technologies from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Finally, Wall Street Zen upgraded DBV Technologies from a “sell” rating to a “hold” rating in a research note on Friday, November 28th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $28.05.

DBV Technologies Stock Down 0.4%

Shares of NASDAQ DBVT opened at $18.29 on Monday. DBV Technologies has a fifty-two week low of $2.74 and a fifty-two week high of $21.50. The business has a 50 day moving average price of $14.90 and a two-hundred day moving average price of $11.51. The firm has a market cap of $734.53 million, a PE ratio of -3.54 and a beta of -1.10.

Institutional Investors Weigh In On DBV Technologies

Several institutional investors and hedge funds have recently bought and sold shares of DBVT. New York State Common Retirement Fund bought a new position in DBV Technologies in the third quarter worth about $34,000. Two Sigma Investments LP acquired a new stake in shares of DBV Technologies during the 3rd quarter worth approximately $167,000. Citadel Advisors LLC bought a new stake in shares of DBV Technologies in the 3rd quarter worth approximately $220,000. DLD Asset Management LP acquired a new position in DBV Technologies during the 3rd quarter valued at approximately $250,000. Finally, Nan Fung Trinity HK Ltd. bought a new position in DBV Technologies during the 2nd quarter worth $340,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.